Shattuck Labs, Inc. (STTK)
NASDAQ:STTK
Want to see STTK full AI Analyst Report?
STTK Stock Chart & Stats
$7.17
>-$0.01(-0.39%)
At close: 4:00 PM EST
$7.17
>-$0.01(-0.39%)
Day’s Range― - ―
52-Week Range$0.71 - $7.68
Previous CloseN/A
Volume43.14K
Average Volume (3M)679.74K
Market Cap
$513.12M
Enterprise Value$299.48M
Total Cash (Recent Filing)$54.19M
Total Debt (Recent Filing)$1.58M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
May 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding71,564,220
10 Day Avg. Volume430,974
30 Day Avg. Volume679,739
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue299.48
Enterprise Value/Gross Profit-169.10
Enterprise Value/Ebitda-6.44
Forecast
1Y Price Target
$10.00Price Target Upside39.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Mechanism Of ActionAnalyst emphasizes DR3 antagonism as a differentiated therapeutic approach that may block the DR3‑TL1A pathway more effectively than existing TL1A antibodies, potentially improving treatment efficacy in inflammatory bowel diseases.
Phase 1 Clinical Data CatalystAnalyst highlights initial Phase 1 results for SL-325 as a major catalyst because safety, receptor occupancy, and immunogenicity readouts could clarify differentiation versus competing anti-TL1A therapies and lead to a reassessment of clinical potential.
Strengthened Financial RunwayAnalyst notes that a strengthened balance sheet from completed financing provides capital to advance multiple clinical programs and reduces near‑term financing risk for SL-325 development.
Bears Say
Clinical, Regulatory And Commercial UncertaintyAnalyst flags combined clinical, regulatory, financing, and commercial risks that could delay development or limit market opportunity, creating elevated uncertainty for investor outcomes.
Immunogenicity RiskAnalyst warns that previous anti‑TL1A therapies often induced anti‑drug antibodies that reduced drug exposure and efficacy, creating a meaningful immunogenicity risk for SL-325.
Reliance On Future Clinical SuccessAnalyst points to reported operating losses as an indication that the company's valuation depends heavily on future clinical successes, increasing downside if programs do not meet expectations.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs, Inc.’s price range in the past 12 months?
Shattuck Labs, Inc. lowest stock price was $0.71 and its highest was $7.68 in the past 12 months.
What is Shattuck Labs, Inc.’s market cap?
Shattuck Labs, Inc.’s market cap is $513.12M.
When is Shattuck Labs, Inc.’s upcoming earnings report date?
Shattuck Labs, Inc.’s upcoming earnings report date is May 13, 2026 which is in 26 days.
How were Shattuck Labs, Inc.’s earnings last quarter?
Shattuck Labs, Inc. released its earnings results on Mar 05, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.016.
Is Shattuck Labs, Inc. overvalued?
According to Wall Street analysts Shattuck Labs, Inc.’s price is currently Undervalued.
Does Shattuck Labs, Inc. pay dividends?
Shattuck Labs, Inc. does not currently pay dividends.
What is Shattuck Labs, Inc.’s EPS estimate?
Shattuck Labs, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Shattuck Labs, Inc. have?
Shattuck Labs, Inc. has 71,564,220 shares outstanding.
What happened to Shattuck Labs, Inc.’s price movement after its last earnings report?
Shattuck Labs, Inc. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 7.822%.
Which hedge fund is a major shareholder of Shattuck Labs, Inc.?
Currently, no hedge funds are holding shares in STTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (39.47% Upside)
$10.00 (39.47% Upside)
Blogger Sentiment
Bullish
STTK Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.4%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
873.50%
12-Months-Change
Fundamentals
Return on Equity
-65.03%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$10.00
▲(39.47% Upside)
Technical Analysis
PolyPid
―
Coeptis Therapeutics Holdings
―
―
Xilio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
14.50% Insiders
6.19% Mutual Funds
40.37% Other Institutional Investors
35.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---